福泰制药- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于福泰制药公司

福泰制药orporated 是一家全球性生物技术公司。该公司专注于投资科学创新，为患有严重疾病的人创造变革性药物，重点关注专业市场。该公司拥有四种获批的治疗囊性纤维化 (CF) 潜在病因的药物，以及一种获批的治疗严重镰状细胞病 (SCD) 和输血依赖性β地中海贫血 (TDT) 的疗法。其产品线包括 CF、SCD、TDT、急性和神经性疼痛、APOL1 介导的肾脏疾病、1 型糖尿病、1 型肌强直性营养不良和 α-1 抗胰蛋白酶缺乏症的临床阶段项目。其上市药物包括 TRIKAFTA/KAFTRIO、SYMDEKO/SYMKEVI（tezacaftor/ivacaftor 和 ivacaftor）、ORKAMBI（lumacaftor/ivacaftor）和 KALYDECO（ivacaftor）。该公司正在开发非自体（同种异体）完全分化、干细胞衍生的胰岛细胞疗法，旨在取代 1 型糖尿病患者体内被破坏的产生胰岛素的胰岛细胞。

福泰制药简介



公司代码VRTX

公司名称Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

CEODr. Reshma Kewalramani

员工数量6100

证券类型Ordinary Share

年结日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02210

电话16173416393

网址https://www.vrtx.com/

公司代码VRTX

上市日期Jul 24, 1991

CEODr. Reshma Kewalramani

福泰制药公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

15.65K

-11.09%

Mr. Lloyd A. Carney

Independent Director

7.12K

+12.60%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-5.51%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

名称

名称/职务

职务

持股

持股变动

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

地区USD

名称

营收

占比

United States

1.83B

62.08%

Europe

910.90M

30.94%

Other

205.60M

6.98%

业务

地区

业务USD

名称

营收

占比

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

股东统计

更新时间: 8月17日周日

持股股东

股东类型

持股股东

占比

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

4.59%

其他

63.09%

持股股东

占比

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

4.59%

其他

63.09%

股东类型

持股股东

占比

Investment Advisor

60.58%

Investment Advisor/Hedge Fund

27.28%

Research Firm

2.54%

Pension Fund

2.27%

Bank and Trust

2.01%

Sovereign Wealth Fund

1.49%

Hedge Fund

0.70%

Individual Investor

0.14%

Insurance Company

0.12%

其他

2.88%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

2924

248.95M

97.09%

-3.97M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Capital World Investors

28.73M

11.21%

+198.84K

+0.70%

Jun 30, 2025

The Vanguard Group, Inc.

23.86M

9.31%

+479.23K

+2.05%

Jun 30, 2025

Capital Research Global Investors

16.11M

6.28%

+1.57M

+10.81%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

14.15M

5.52%

+156.31K

+1.12%

Jun 30, 2025

State Street Investment Management (US)

11.78M

4.59%

-13.43K

-0.11%

Jun 30, 2025

Fidelity Management & Research Company LLC

6.30M

2.46%

-1.32M

-17.28%

Jun 30, 2025

Geode Capital Management, L.L.C.

5.93M

2.31%

+166.99K

+2.90%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

5.26M

2.05%

-18.59K

-0.35%

Aug 31, 2025

Wellington Management Company, LLP

4.81M

1.88%

-641.36K

-11.76%

Jun 30, 2025

AllianceBernstein L.P.

4.38M

1.71%

+424.81K

+10.75%

Jun 30, 2025

持股ETF



更新时间: 11月1日周六

机构名称

占比

VanEck Biotech ETF

9.42%

ProShares Ultra Nasdaq Biotechnology

8.56%

Invesco Nasdaq Biotechnology ETF

8.38%

iShares Biotechnology ETF

7.31%

Invesco Biotechnology & Genome ETF

4.96%

Natixis Loomis Sayles Focused Growth ETF

3.75%

First Trust NASDAQ Pharmaceuticals ETF

3.68%

Franklin Genomic Advancements ETF

2.99%

ETC 6 Meridian Quality Growth ETF

2.96%

Global X Genomics & Biotechnology ETF

2.83%

VanEck Biotech ETF

占比9.42%

ProShares Ultra Nasdaq Biotechnology

占比8.56%

Invesco Nasdaq Biotechnology ETF

占比8.38%

iShares Biotechnology ETF

占比7.31%

Invesco Biotechnology & Genome ETF

占比4.96%

Natixis Loomis Sayles Focused Growth ETF

占比3.75%

First Trust NASDAQ Pharmaceuticals ETF

占比3.68%

Franklin Genomic Advancements ETF

占比2.99%

ETC 6 Meridian Quality Growth ETF

占比2.96%

Global X Genomics & Biotechnology ETF

占比2.83%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

福泰制药

关于 福泰制药 公司

福泰制药简介

福泰制药公司高管

收入明细

股东统计

机构持股

股东持股明细

持股ETF

分红派息

拆合股

关于福泰制药公司